Please assess the completion status of the following clinical trial:

Trial Title: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Females aged greater than or equal to 20 years and less than 75 years at the time of informed consent.~* Histologically or cytologically confirmed with breast cancer~* Score 3+ by immunohistochemistry (IHC) or HER2 positive by Fluorescence in Situ Hybridization (FISH) method~* Subjects who meet any of the following criteria:~  * Evidence of recurrence during adjuvant chemotherapy with trastuzumab and taxane~ * Evidence of recurrence within 6 months after adjuvant chemotherapy with trastuzumab and taxane~ * Experienced prior chemotherapy including trastuzumab and taxane for advanced or recurrent breast cancer~* Adequate organ function~* Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) is 0 or 1~* Subjects who have submitted written informed consent for study entry~Exclusion Criteria~* Subjects with known brain metastasis accompanied by clinical symptoms or requiring active treatment~* Subjects with severe active infection requiring active treatment~* Subjects with large pleural effusions, ascites, or pericardial effusions requiring drainage.~* Hypersensitivity to trastuzumab, halicondrin B or halicondrin B chemical derivatives~* Known positive for human immunodeficiency virus (HIV) test or positive for hepatitis B surface (HBs antigen) or hepatitis C (HCV) by serum test.~* Subjects who are pregnant (positive B-hCG test) or breastfeeding~* Subjects judged to be ineligible for this study by the principal investigator or sub-investigator.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).